{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:33Z","timestamp":1791646473324,"version":"4.3.4"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40265-021-01646-3","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T09:03:02Z","timestamp":1637917382000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2194-1478","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Mart\u00ednez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2121-7554","authenticated-orcid":false,"given":"Grace","family":"Oscullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Garc\u00eda-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7801-5040","authenticated-orcid":false,"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"issue":"4","key":"1646_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.arbr.2018.09.013","volume":"55","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2019","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, Agust\u00ed A. Heterogeneity and complexity in bronchiectasis: a pending challenge. Arch Bronconeumol (Engl Ed). 2019;55(4):187\u20138.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"issue":"4","key":"1646_CR2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1183\/13993003.01899-2015","volume":"47","author":"S Aliberti","year":"2016","unstructured":"Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J. 2016;47(4):1113\u201322.","journal-title":"Eur Respir J"},{"issue":"5","key":"1646_CR3","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.chest.2020.11.011","volume":"159","author":"L Perea","year":"2021","unstructured":"Perea L, Canto E, Suarez-Cuartin G, Aliberti S, Chalmers JD, Sibila O, et al. A cluster analysis of bronchiectasis patients based on the airway immune profile. Chest. 2021;159(5):1758\u201367.","journal-title":"Chest"},{"issue":"9","key":"1646_CR4","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1513\/AnnalsATS.201510-678OC","volume":"13","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2016","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, Vendrell M, Gir\u00f3n R, M\u00e1iz-Carro L, de la Rosa CD, de Gracia J, et al. The multiple faces of non-cystic fibrosis bronchiectasis. A cluster analysis approach. Ann Am Thorac Soc. 2016;13(9):1468\u201375.","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"1646_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.arbr.2019.06.004","volume":"55","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2019","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, Olveira C, M\u00e1iz L, Gir\u00f3n RM, Prados C, de la Rosa D, et al. Bronchiectasis: a complex, heterogeneous disease. Arch Bronconeumol (Engl Ed). 2019;55(8):427\u201333.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"issue":"4","key":"1646_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.arbr.2019.02.005","volume":"55","author":"I Garcia-Oliv\u00e9","year":"2019","unstructured":"Garcia-Oliv\u00e9 I, Marin A, Rodr\u00edguez-Pons L, Abad J. Trends in admission for bronchiectasis in a third-level hospital (2008\u20132017). Arch Bronconeumol (Engl Ed). 2019;55(4):217\u20138.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"issue":"4","key":"1646_CR7","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-021-01289-7","volume":"27","author":"M Mac Aog\u00e1in","year":"2021","unstructured":"Mac Aog\u00e1in M, Narayana JK, Tiew PY, Ali NABM, Yong VFL, Jaggi TK, et al. Integrative microbiomics in bronchiectasis exacerbations. Nat Med. 2021;27(4):688\u201399.","journal-title":"Nat Med"},{"issue":"1","key":"1646_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.arbr.2019.12.022","volume":"57","author":"T Posadas","year":"2021","unstructured":"Posadas T, Oscullo G, Zaldivar E, Villa C, Dobarganes Y, Gir\u00f3n R, et al. C-reactive protein concentration in steady-state bronchiectasis: prognostic value of future severe exacerbations. Data from the Spanish Registry of Bronchiectasis (RIBRON). Arch Bronconeumol (Engl Ed). 2021;57(1):21\u20137.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"issue":"11","key":"1646_CR9","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","volume":"197","author":"JD Chalmers","year":"2018","unstructured":"Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, et al. Characterization of the \u201cfrequent exacerbator phenotype\u201d in bronchiectasis. Am J Respir Crit Care Med. 2018;197(11):1410\u201320.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"1646_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.arbr.2019.12.014","volume":"56","author":"CL Chen","year":"2020","unstructured":"Chen CL, Huang Y, Yuan JJ, Li HM, Han XR, Mart\u00ednez-Garc\u00eda M\u00c1, et al. The roles of bacteria and viruses in bronchiectasis exacerbation: a prospective study. Arch Bronconeumol (Engl Ed). 2020;56(10):621\u20139.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"issue":"7","key":"1646_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.arbr.2017.05.005","volume":"53","author":"C Olveira","year":"2017","unstructured":"Olveira C, Padilla A, Mart\u00ednez-Garc\u00eda M\u00c1, de la Rosa D, Gir\u00f3n RM, Vendrell M, et al. Etiology of bronchiectasis in a cohort of 2047 patients. An analysis of the Spanish Historical Bronchiectasis Registry. Arch Bronconeumol (Engl Ed). 2017;53(7):366\u201374.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"issue":"12","key":"1646_CR12","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1513\/AnnalsATS.201507-472OC","volume":"12","author":"S Lonni","year":"2015","unstructured":"Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc. 2015;12(12):1764\u201370.","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"1646_CR13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.arbr.2018.10.016","volume":"55","author":"M Redondo","year":"2019","unstructured":"Redondo M, Chalmers JD. Bronchiectasis guidelines-recommendations into practice. Arch Bronconeumol (Engl Ed). 2019;55(6):286\u20138.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"issue":"6","key":"1646_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.arbr.2019.05.009","volume":"55","author":"M\u00c1 Martinez-Garcia","year":"2019","unstructured":"Martinez-Garcia M\u00c1, de la Rosa D, Cant\u00f3n R, Olveira C, M\u00e1iz-Carro L, Gir\u00f3n R, et al. Bronchiectasis: when the published scientific evidence proves insufficient. Arch Bronconeumol (Engl Ed). 2019;55(6):283\u20135.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"key":"1646_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.rmed.2018.10.031","volume":"145","author":"D Radovanovic","year":"2018","unstructured":"Radovanovic D, Santus P, Blasi F, Sotgiu G, D\u2019Arcangelo F, Simonetta E, et al. A comprehensive approach to lung function in bronchiectasis. Respir Med. 2018;145:120\u20139.","journal-title":"Respir Med"},{"key":"1646_CR16","doi-asserted-by":"publisher","first-page":"109219","DOI":"10.1155\/2013\/109219","volume":"2013","author":"M Luj\u00e1n","year":"2013","unstructured":"Luj\u00e1n M, Gallardo X, Amengual MJ, Bosque M, Mirapeix RM, Domingo C. Prevalence of bronchiectasis in asthma according to oral steroid requirement: influence of immunoglobulin levels. Biomed Res Int. 2013;2013:109219.","journal-title":"Biomed Res Int"},{"issue":"4","key":"1646_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.chest.2018.02.024","volume":"154","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2018","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, Polverino E, Aksamit T. Bronchiectasis and chronic airway disease: it is not just about asthma and COPD. Chest. 2018;154(4):737\u20139.","journal-title":"Chest"},{"issue":"10","key":"1646_CR18","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.arbr.2020.06.003","volume":"56","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2020","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, Posadas T, Sotgiu S, et al. Repeteability of circulating eosinophil measures and inhaled corticosteroids effect in bronchiectasis. A post hoc analysis of a randomized clinical trial. Arch Bronconeumol (Engl Ed). 2020;56(10):681\u20133.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"issue":"1","key":"1646_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.arbr.2019.04.014","volume":"56","author":"E Mons\u00f3","year":"2020","unstructured":"Mons\u00f3 E. Look at the wood and not at the tree: the microbiome in chronic obstructive lung disease and cystic fibrosis. Arch Bronconeumol (Engl Ed). 2020;56(1):5\u20136.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"key":"1646_CR20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1146\/annurev-pathol-012615-044344","volume":"11","author":"RJ Boyton","year":"2016","unstructured":"Boyton RJ, Altmann DM. Bronchiectasis: current concepts in pathogenesis, immunology, and microbiology. Annu Rev Pathol. 2016;11:523\u201354.","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"1646_CR21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1183\/09031936.00069007","volume":"31","author":"S Fuschillo","year":"2008","unstructured":"Fuschillo S, de Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J. 2008;31(2):396\u2013406.","journal-title":"Eur Respir J"},{"issue":"3","key":"1646_CR22","doi-asserted-by":"publisher","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","volume":"50","author":"E Polverino","year":"2017","unstructured":"Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"1646_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","volume":"74","author":"AT Hill","year":"2019","unstructured":"Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn JS, Floto RA, et al. British Thoracic Society guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1\u201369.","journal-title":"Thorax"},{"issue":"2","key":"1646_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.arbr.2017.07.014","volume":"54","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2018","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, M\u00e1iz L, Olveira C, Gir\u00f3n RM, de la Rosa D, Blanco M, et al. Spanish guidelines on treatment of bronchiectasis in adults. Arch Bronconeumol (Engl Ed). 2018;54(2):88\u201398.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"issue":"1","key":"1646_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5694\/mjac14.00287","volume":"202","author":"AB Chang","year":"2015","unstructured":"Chang AB, Bell SC, Torzillo PJ, King PT, Maguire GP, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Thoracic Society of Australia and New Zealand guidelines. Med J Aust. 2015;202(1):130.","journal-title":"Med J Aust"},{"issue":"3","key":"1646_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4103\/atm.ATM_171_17","volume":"12","author":"H Al-Jahdali","year":"2017","unstructured":"Al-Jahdali H, Alshimemeri A, Mobeireek A, Albanna AS, Al Shirawi NN, Wali S, et al. The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis. Ann Thorac Med. 2017;12(3):135\u201361.","journal-title":"Ann Thorac Med."},{"issue":"11","key":"1646_CR27","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.rmed.2007.06.028","volume":"101","author":"MA Mart\u00ednez-Garc\u00eda","year":"2007","unstructured":"Mart\u00ednez-Garc\u00eda MA, Perpi\u00f1\u00e1-Tordera M, Soler-Catalu\u00f1a JJ, Rom\u00e1n-S\u00e1nchez P, Lloris-Bayo A, Gonz\u00e1lez-Molina A. Dissociation of lung function, dyspnea ratings and pulmonary extension in bronchiectasis. Respir Med. 2007;101(11):2248\u201353.","journal-title":"Respir Med"},{"issue":"5","key":"1646_CR28","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1183\/09031936.00026313","volume":"43","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2014","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, de Gracia J, Vendrell Relat M, Gir\u00f3n RM, M\u00e1iz Carro L, de la Rosa CD, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. 2014;43(5):1357\u201367.","journal-title":"Eur Respir J"},{"issue":"5","key":"1646_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","volume":"189","author":"JD Chalmers","year":"2014","unstructured":"Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576\u201385.","journal-title":"Am J Respir Crit Care Med"},{"key":"1646_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2147\/COPD.S121943","volume":"12","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2017","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, Athanazio RA, Gir\u00f3n R, M\u00e1iz-Carro L, de la Rosa D, Olveira C, de Gracia J, et al. Predicting high risk of exacerbations in bronchiectasis: the E-FACED score. Int J Chron Obstruct Pulmon Dis. 2017;12:275\u201384.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"12","key":"1646_CR31","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/thoraxjnl-2016-208481","volume":"71","author":"MJ McDonnell","year":"2016","unstructured":"McDonnell MJ, Aliberti S, Goeminne PC, Dimakou K, Zucchetti SC, Davidson J, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016;71(12):1110\u20138.","journal-title":"Thorax"},{"issue":"1","key":"1646_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.arbr.2020.11.010","volume":"57","author":"M\u00c1 Martinez-Garc\u00eda","year":"2021","unstructured":"Martinez-Garc\u00eda M\u00c1, Villa C, Dobarganes Y, Gir\u00f3n R, Ma\u00edz L, Garc\u00eda-Clemente M, et al. RIBRON: The Spanish Online Bronchiectasis Registry. Characterization of the first 1912 patients. Arch Bronconeumol (Engl Ed). 2021;57(1):28\u201335.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"key":"1646_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12890-017-0417-3","volume":"17","author":"R Athanazio","year":"2017","unstructured":"Athanazio R, Pereira MC, Gramblicka G, Cavalcanti-Lundgren F, de Figueiredo MF, Arancibia F, et al. Latin America validation of FACED score in patients with bronchiectasis: an analysis of six cohorts. BMC Pulm Med. 2017;17:73.","journal-title":"BMC Pulm Med"},{"issue":"9","key":"1646_CR34","doi-asserted-by":"publisher","first-page":"e1269","DOI":"10.1016\/S2214-109X(19)30327-4","volume":"7","author":"R Dhar","year":"2019","unstructured":"Dhar R, Singh S, Talwar D, Mohan M, Tripathi SK, Swarnakar R, et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. Lancet Glob Health. 2019;7(9):e1269\u201379.","journal-title":"Lancet Glob Health"},{"issue":"7","key":"1646_CR35","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.arbres.2019.09.002","volume":"56","author":"JM D\u00edaz L\u00f3pez","year":"2020","unstructured":"D\u00edaz L\u00f3pez JM, Giran Gonz\u00e1lez B, Alc\u00e1zar-Navarrete B. Personalized medicine in chronic obstructive pulmonary disease: how close are we? Arch Bronconeumol. 2020;56(7):420\u20131.","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"1646_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.arbr.2020.03.023","volume":"57","author":"B Celli","year":"2021","unstructured":"Celli B, Divo M, Pinto PV. Pharmacotherapy Impacts on COPD mortality. Arch Bronconeumol (Engl Ed). 2021;57(1):5\u20136.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"issue":"1","key":"1646_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.arbr.2020.11.004","volume":"57","author":"M Miravitlles","year":"2021","unstructured":"Miravitlles M, Calle M, Soler-Catalu\u00f1a JJ. GesEPOC 2021: one more step towards personalized treatment of COPD. Arch Bronconeumol (Engl Ed). 2021;57(1):9\u201310.","journal-title":"Arch Bronconeumol (Engl Ed)."},{"issue":"3","key":"1646_CR38","doi-asserted-by":"publisher","first-page":"1801269","DOI":"10.1183\/13993003.01269-2018","volume":"52","author":"R Boaventura","year":"2018","unstructured":"Boaventura R, Sibila O, Agust\u00ed A, Chalmers JD. Treatable traits in bronchiectasis. Eur Respir J. 2018;52(3):1801269.","journal-title":"Eur Respir J"},{"issue":"1","key":"1646_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1164\/rccm.201903-0604PP","volume":"201","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2020","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, Aksamit TR, Agust\u00ed A. Clinical fingerprinting: a way to address the complexity and heterogeneity of bronchiectasis in practice. Am J Respir Crit Care Med. 2020;201(1):14\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1646_CR40","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00408-019-00280-x","volume":"197","author":"SK Visser","year":"2019","unstructured":"Visser SK, Bye PTP, Fox GJ, Burr LD, Chang AB, Holmes-Liew CL, et al. Management of Australian adults with bronchiectasis in tertiary care: evidence-based or access-driven? Lung. 2019;197(6):803\u201310.","journal-title":"Lung"},{"issue":"5","key":"1646_CR41","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.chest.2016.10.055","volume":"151","author":"TR Aksamit","year":"2017","unstructured":"Aksamit TR, O\u2019Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels MLA, et al. Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry. Chest. 2017;151(5):982\u201392.","journal-title":"Chest"},{"issue":"5","key":"1646_CR42","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1378\/chest.07-0490","volume":"132","author":"M\u00c1 Martinez-Garc\u00eda","year":"2007","unstructured":"Martinez-Garc\u00eda M\u00c1, Soler-Catalu\u00f1a JJ, Perpi\u00f1\u00e1-Tordera M, Rom\u00e1n-S\u00e1nchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132(5):1565\u201372.","journal-title":"Chest"},{"issue":"3","key":"1646_CR43","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.cmi.2020.04.007","volume":"27","author":"M\u00c1 Martinez-Garc\u00eda","year":"2021","unstructured":"Martinez-Garc\u00eda M\u00c1, Oscullo G, Posadas T, Zaldivar E, Villa C, Dobarganes Y, et al. Pseudomonas aeruginosa and lung function decline in patients with bronchiectasis. Clin Microbiol Infect. 2021;27(3):428\u201334.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"1646_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1124\/pr.111.004580","volume":"64","author":"M Cazzola","year":"2012","unstructured":"Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450\u2013504.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1646_CR45","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ccm.2013.10.005","volume":"35","author":"M Cazzola","year":"2014","unstructured":"Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med. 2014;35(1):191\u2013201.","journal-title":"Clin Chest Med"},{"issue":"1","key":"1646_CR46","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1124\/pr.119.018150","volume":"72","author":"MG Matera","year":"2020","unstructured":"Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev. 2020;72(1):218\u201352.","journal-title":"Pharmacol Rev"},{"issue":"7","key":"1646_CR47","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1111\/all.14766","volume":"76","author":"M Cazzola","year":"2021","unstructured":"Cazzola M, Calzetta L, Matera MG. Long-acting muscarinic antagonists and small airways in asthma: Which link? Allergy. 2021;76(7):1990\u20132001.","journal-title":"Allergy"},{"issue":"4","key":"1646_CR48","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1042\/cs0780409","volume":"78","author":"RK Sharma","year":"1990","unstructured":"Sharma RK, Jeffery PK. Airway \u03b2-adrenoceptor number in cystic fibrosis and asthma. Clin Sci (Lond). 1990;78(4):409\u201317.","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"1646_CR49","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1046\/j.1440-1843.1999.00215.x","volume":"4","author":"JA Hassan","year":"1999","unstructured":"Hassan JA, Saadiah S, Roslan H, Zainudin BM. Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis. Respirology. 1999;4(4):423\u20136.","journal-title":"Respirology"},{"key":"1646_CR50","first-page":"OA4944","volume":"54","author":"GM de Koning","year":"2019","unstructured":"de Koning GM, Kamphuis LSJ, Hoek RAS, Bakker M, Aerts JGJV, Van Der Eerden MM. Airway hyperresponsiveness in bronchiectasis. Eur Respir J. 2019;54:OA4944.","journal-title":"Eur Respir J"},{"issue":"8","key":"1646_CR51","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1164\/rccm.200707-977OC","volume":"177","author":"N Regamey","year":"2008","unstructured":"Regamey N, Ochs M, Hilliard TN, M\u00fchlfeld C, Cornish N, Fleming L, et al. Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2008;177(8):837\u201343.","journal-title":"Am J Respir Crit Care Med"},{"key":"1646_CR52","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/COPD.S6133","volume":"4","author":"PT King","year":"2009","unstructured":"King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2009;4:411\u20139.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1646_CR53","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2147\/COPD.S132961","volume":"12","author":"MA Martinez-Garcia","year":"2017","unstructured":"Martinez-Garcia MA, Miravitlles M. Bronchiectasis in COPD patients: more than a comorbidity? Int J Chron Obstruct Pulmon Dis. 2017;12:1401\u201311.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"1646_CR54","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1513\/pats.200504-033SR","volume":"2","author":"BJ Undem","year":"2005","unstructured":"Undem BJ, Kollarik M. The role of vagal afferent nerves in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):355\u201360.","journal-title":"Proc Am Thorac Soc"},{"issue":"4","key":"1646_CR55","doi-asserted-by":"publisher","first-page":"1701247","DOI":"10.1183\/13993003.01247-2017","volume":"52","author":"R Gosens","year":"2018","unstructured":"Gosens R, Gross N. The mode of action of anticholinergics in asthma. Eur Respir J. 2018;52(4):1701247.","journal-title":"Eur Respir J"},{"issue":"3","key":"1646_CR56","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.tips.2014.11.005","volume":"36","author":"LE Kistemaker","year":"2015","unstructured":"Kistemaker LE, Gosens R. Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. Trends Pharmacol Sci. 2015;36(3):164\u201371.","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"1646_CR57","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1183\/09031936.00129307","volume":"32","author":"S Haag","year":"2008","unstructured":"Haag S, Matthiesen S, Juergens UR, Rack\u00e9 K. Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts. Eur Respir J. 2008;32(3):555\u201362.","journal-title":"Eur Respir J"},{"issue":"6","key":"1646_CR58","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1183\/09031936.00017712","volume":"41","author":"J Milara","year":"2013","unstructured":"Milara J, Serrano A, Peir\u00f3 T, Artigues E, Gavald\u00e0 A, Miralpeix M, et al. Aclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transition. Eur Respir J. 2013;41(6):1264\u201374.","journal-title":"Eur Respir J"},{"key":"1646_CR59","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/164_2016_68","volume":"237","author":"MG Matera","year":"2017","unstructured":"Matera MG, Cazzola M. Muscarinic receptor antagonists. Handb Exp Pharmacol. 2017;237:41\u201362.","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"1646_CR60","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12931-016-0386-8","volume":"17","author":"M Cazzola","year":"2016","unstructured":"Cazzola M, Calzetta L, Puxeddu E, Ora J, Facciolo F, Rogliani P, et al. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respir Res. 2016;17(1):70.","journal-title":"Respir Res"},{"key":"1646_CR61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pupt.2019.03.004","volume":"56","author":"L Calzetta","year":"2019","unstructured":"Calzetta L, Rogliani P, Page C, Rinaldi B, Cazzola M, Matera MG. Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. Pulm Pharmacol Ther. 2019;56:39\u201350.","journal-title":"Pulm Pharmacol Ther"},{"issue":"3","key":"1646_CR62","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.21037\/jtd.2018.02.13","volume":"10","author":"ZG Chen","year":"2018","unstructured":"Chen ZG, Li YY, Wang ZN, Li M, Lim HF, Zhou YQ, et al. Aberrant epithelial remodeling with impairment of cilia architecture in non-cystic fibrosis bronchiectasis. J Thorac Dis. 2018;10(3):1753\u201364.","journal-title":"J Thorac Dis"},{"issue":"1","key":"1646_CR63","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0014-2999(83)90058-4","volume":"87","author":"AJ Schreurs","year":"1983","unstructured":"Schreurs AJ, Verhoef J, Nijkamp FP. Bacterial cell wall components decrease the number of guinea-pig lung beta-adrenoceptors. Eur J Pharmacol. 1983;87(1):127\u201332.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1646_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02214689","volume":"8","author":"AJ Schreurs","year":"1984","unstructured":"Schreurs AJ, Nijkamp FP. Haemophilus influenzae and the beta-adrenergic system: a review. Vet Res Commun. 1984;8(1):1\u201314.","journal-title":"Vet Res Commun"},{"issue":"1","key":"1646_CR65","first-page":"157","volume":"13","author":"M Cazzola","year":"1991","unstructured":"Cazzola M, Matera MG, Rossi F. Bronchial hyperresponsiveness and bacterial respiratory infections. Clin Ther. 1991;13(1):157\u201371.","journal-title":"Clin Ther"},{"issue":"4","key":"1646_CR66","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/j.1476-5381.1991.tb12526.x","volume":"104","author":"PJ Henry","year":"1991","unstructured":"Henry PJ, Rigby PJ, Mackenzie JS, Goldie RG. Effect of respiratory tract viral infection on murine airway beta-adrenoceptor function, distribution and density. Br J Pharmacol. 1991;104(4):914\u201321.","journal-title":"Br J Pharmacol"},{"issue":"Suppl 15","key":"1646_CR67","first-page":"385s","volume":"5","author":"J Mortensen","year":"1992","unstructured":"Mortensen J, Engel AM, Milman N, Nielsen F, Faurshou P. Inhaled terbutaline improves mucociliary clearance in patients with bronchiectasis. Eur Respir J. 1992;5(Suppl 15):385s.","journal-title":"Eur Respir J"},{"issue":"7","key":"1646_CR68","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2169\/internalmedicine.47.0568","volume":"47","author":"Y Saito","year":"2008","unstructured":"Saito Y, Azuma A, Morimoto T, Fujita K, Abe S, Motegi T, et al. Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to macrolide therapy. Intern Med. 2008;47(7):585\u201391.","journal-title":"Intern Med"},{"issue":"5","key":"1646_CR69","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/thx.33.5.635","volume":"33","author":"SG Nogrady","year":"1978","unstructured":"Nogrady SG, Evans WV, Davies BH. Reversibility of airways obstruction in bronchiectasis. Thorax. 1978;33(5):635\u20137.","journal-title":"Thorax"},{"issue":"1","key":"1646_CR70","first-page":"14","volume":"8","author":"WJ Guan","year":"2016","unstructured":"Guan WJ, Gao YH, Xu G, Li HM, Yuan JJ, Zheng JP, et al. Bronchodilator response in adults with bronchiectasis: correlation with clinical parameters and prognostic implications. J Thorac Dis. 2016;8(1):14\u201323.","journal-title":"J Thorac Dis"},{"key":"1646_CR71","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.2147\/COPD.S115581","volume":"11","author":"HJ Jeong","year":"2016","unstructured":"Jeong HJ, Lee H, Carriere KC, Kim JH, Han JH, Shin B, et al. Effects of long-term bronchodilators in bronchiectasis patients with airflow limitation based on bronchodilator response at baseline. Int J Chron Obstruct Pulmon Dis. 2016;11:2757\u201364.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"1646_CR72","doi-asserted-by":"publisher","first-page":"169","DOI":"10.21037\/jtd-20-1282","volume":"13","author":"SY Lee","year":"2021","unstructured":"Lee SY, Lee JS, Lee SW, Oh YM. Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study. J Thorac Dis. 2021;13(1):169\u201377.","journal-title":"J Thorac Dis"},{"key":"1646_CR73","doi-asserted-by":"publisher","unstructured":"Jayaram L, Vandal AC, Chang C, Lewis C, Tong C, Tuffery C, et al. Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial. Eur Respir J.\u00a02021. https:\/\/doi.org\/10.1183\/13993003.02184-2021. (in press).","DOI":"10.1183\/13993003.02184-2021"},{"key":"1646_CR74","first-page":"CD002155","volume":"4","author":"A Sheikh","year":"2001","unstructured":"Sheikh A, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev. 2001;4:CD002155.","journal-title":"Cochrane Database Syst Rev"},{"key":"1646_CR75","first-page":"CD002163","volume":"4","author":"T Lasserson","year":"2001","unstructured":"Lasserson T, Holt K, Evans D, Greenstone M. Anticholinergic therapy for bronchiectasis. Cochrane Database Syst Rev. 2001;4:CD002163.","journal-title":"Cochrane Database Syst Rev"},{"key":"1646_CR76","first-page":"CD003572","volume":"3","author":"F Franco","year":"2003","unstructured":"Franco F, Sheikh A, Greenstone M. Short acting beta-2 agonists for bronchiectasis. Cochrane Database Syst Rev. 2003;3:CD003572.","journal-title":"Cochrane Database Syst Rev"},{"key":"1646_CR77","first-page":"CD010327","volume":"6","author":"V Goyal","year":"2014","unstructured":"Goyal V, Chang AB. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis. Cochrane Database Syst Rev. 2014;6:CD010327.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1646_CR78","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1378\/chest.11-0180","volume":"141","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2012","unstructured":"Mart\u00ednez-Garc\u00eda M\u00c1, Soler-Catalu\u00f1a JJ, Catal\u00e1n-Serra P, Rom\u00e1n-S\u00e1nchez P, Tordera MP. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012;141(2):461\u20138.","journal-title":"Chest"},{"key":"1646_CR79","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3389\/fphar.2019.01409","volume":"10","author":"JJ Yeh","year":"2019","unstructured":"Yeh JJ, Yang YC, Hsu CY, Kao CH. Effect of bronchodilator and steroid use on heart disease and stroke risks in a bronchiectasis-chronic obstructive pulmonary disease overlap cohort: a propensity score matching study. Front Pharmacol. 2019;10:1409.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1646_CR80","doi-asserted-by":"publisher","first-page":"363","DOI":"10.5588\/ijtld.13.0255","volume":"18","author":"JK Lee","year":"2014","unstructured":"Lee JK, Lee J, Park SS, Heo EY, Park YS, Lee CH, et al. Effect of inhalers on the development of haemoptysis in patients with non-cystic fibrosis bronchiectasis. Int J Tuberc Lung Dis. 2014;18(3):363\u201370.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"1646_CR81","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/resp.12618","volume":"20","author":"EJ Jang","year":"2015","unstructured":"Jang EJ, Lee CH, Yoon HI, Kim YJ, Kim JM, Choi SM, et al. Association between inhaler use and risk of haemoptysis in patients with on-cystic fibrosis bronchiectasis. Respirology. 2015;20(8):1213\u201321.","journal-title":"Respirology"},{"issue":"5","key":"1646_CR82","first-page":"1072","volume":"30","author":"XL Li","year":"2010","unstructured":"Li XL, Cai SX, Zhao HJ, Dong LM, Shen XB, Liu LY, et al. Therapeutic effect of tiotropium bromide powder inhalation in patients with stable bronchiectasis (Chinese). Nan Fang Yi Ke Da Xue Xue Bao. 2010;30(5):1072\u20134.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"154","key":"1646_CR83","doi-asserted-by":"publisher","first-page":"190095","DOI":"10.1183\/16000617.0095-2019","volume":"28","author":"M Cazzola","year":"2019","unstructured":"Cazzola M, Rogliani P, Matera MG. The future of bronchodilation: looking for new classes of bronchodilators. Eur Respir Rev. 2019;28(154):190095.","journal-title":"Eur Respir Rev"},{"issue":"6","key":"1646_CR84","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4155\/ppa-2018-0030","volume":"7","author":"M Cazzola","year":"2018","unstructured":"Cazzola M, Page C, Calzetta L, Matera MG. Ensifentrine (RPL554): an inhaled \u201cbifunctional\u201d dual PDE3\/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. Pharm Pat Anal. 2018;7(6):249\u201357.","journal-title":"Pharm Pat Anal."},{"key":"1646_CR85","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pupt.2015.03.007","volume":"32","author":"L Calzetta","year":"2015","unstructured":"Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3\/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm Pharmacol Ther. 2015;32:15\u201323.","journal-title":"Pulm Pharmacol Ther"},{"key":"1646_CR86","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2147\/COPD.S285867","volume":"16","author":"L Calzetta","year":"2021","unstructured":"Calzetta L, Coppola A, Ritondo BL, Matino M, Chetta A, Rogliani P. The impact of muscarinic receptor antagonists on airway inflammation: a systematic review. Int J Chron Obstruct Pulmon Dis. 2021;16:257\u201379.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"1646_CR87","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jaci.2020.06.014","volume":"146","author":"M Cazzola","year":"2020","unstructured":"Cazzola M, Rogliani P, Matera MG. The latest on the role of LAMAs in asthma. J Allergy Clin Immunol. 2020;146(6):1288\u201391.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01646-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01646-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01646-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T09:34:14Z","timestamp":1710840854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01646-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01646-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,26]]},"assertion":[{"value":"3 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript has not been funded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"M\u00c1M-G: conceptualisation, supervision, writing\u2014original draft, writing\u2014review and editing. GO: systematic clinical review of the literature, writing\u2014review and editing. AG-O: systematic clinical review of the literature, writing\u2014review and editing. MGM: validation, writing\u2014review and editing. PR: validation, writing\u2014review and editing. MC: conceptualisation, supervision, writing\u2014original draft, writing\u2014review and editing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship contribution"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}